FDA reported that the facility is failing to perform adequate product testing and is practicing inadequate labelling or documentation of its drug products, The Globe And Mail reported.
The company was found to have no testing program to assess proper storage conditions or expiry dates.
FDA spokeswoman Shelly Burgess was quoted by the news agency as saying that it takes a risk-based approach depending on the level of risk involved and how severe the potential violation would be to the consumer.